Pediatrix Medical Group, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mark S. Ordan
- Full Time Employees
- 4,120
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- 1301 Concord Terrace Sunrise FL United States of America 33323
- IPO Date
- Sep 20, 1995
- CIK
- 0000893949
- Website
- mednax.com
- Similar Companies
- Business
- Pediatrix Medical Group, Inc. (NYSE: MD) is a physician-led provider of specialized health care services for women, babies, and children across the United States. The company offers maternal-fetal medicine, obstetrical hospitalist services, obstetrics and gynecology care; neonatology including neonatal intensive care units (NICUs), newborn nursery services, and newborn hearing screens; and more than 20 pediatric subspecialties such as cardiology, pulmonology, neurology, gastroenterology, hematology, infectious disease, intensive/critical care, emergency medicine, surgery, and hospitalist services; complemented by telemedicine solutions, telehealth, and evidence-based clinical research support. Pediatrix-affiliated clinicians, numbering approximately 4,400 including over 2,600 physicians, deliver coordinated care in hospital settings and office-based practices, partnering with nearly 400 hospitals and health systems across 36 to 37 states. Founded in 1979 and headquartered in Sunrise, Florida, the company focuses on high-quality, patient-centered outcomes through investments in research, education, quality improvement, safety initiatives, and advanced clinical data utilization. In recent strategic developments, Pediatrix completed a portfolio restructuring in 2024-2025 by divesting its anesthesiology and radiology medical groups as well as its primary and urgent care clinics to refocus on core hospital-based services in neonatology, maternal-fetal medicine, pediatric intensive care, and obstetrics. The company transitioned to a hybrid revenue cycle management model, enhancing collection activity and operational efficiency, which contributed to improved free operating cash flow of $147 million and reduced leverage to 1.1x as of September 30, 2025. Additional changes include leadership transitions with Jim D. Swift, M.D., as CEO, a $250 million share repurchase authorization in August 2025, an S&P credit rating upgrade to 'BB' in November 2025, and raised full-year adjusted EBITDA guidance to $270-$290 million amid targeted small acquisitions in NICUs, maternal-fetal medicine, and obstetric hospitalist operations. These initiatives support same-unit revenue growth of 6.9% year-to-date in 2025 and position the company for low-single-digit volume expansion and modest reimbursement increases.
HSS Chief of Sports Medicine, Riley J. Williams III, MD, Named FIFA Venue Medical Officer for the 2026 World Cup
Here's Why Pediatrix Medical Group (MD) is a Strong Growth Stock
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
Passkey Therapeutics Appoints Mandeep Kaur, MD, MS, as Chief Medical Officer to Advance Clinical Validation of Its Computational Genetics-Based Novel Drug Combination Platform
Here's Why You Should Add Pediatrix Medical to Your Portfolio Now
Why Pediatrix Medical Group (MD) is a Top Momentum Stock for the Long-Term
Pediatrix Medical Group Q1 Earnings Call Highlights
Pediatrix Medical Q1 Earnings Beat Estimates on Same-Unit Strength
Pediatrix Medical Group, Inc. (MD) Q1 2026 Earnings Call Transcript
Pediatrix Medical Group (MD) Q1 Earnings and Revenues Surpass Estimates
Pediatrix Medical Group Reports First Quarter Results
Organon (OGN) Q1 Earnings and Revenues Miss Estimates
Ambience Healthcare Appoints Michael Han, MD, MBA as Chief Medical Officer
Why Pediatrix Medical Group (MD) is a Top Growth Stock for the Long-Term
Pediatrix Medical Group 2026 First Quarter Conference Call/Webcast Scheduled for Tuesday, May 5, 2026
Ritholtz Wealth Management Invests $2.16 Million in Pediatrix Medical Group, Inc. $MD
SG Americas Securities LLC Has $1.56 Million Position in Pediatrix Medical Group, Inc. $MD
Analysts Set Pediatrix Medical Group, Inc. (NYSE:MD) Price Target at $19.80
Here's Why Pediatrix Medical Group (MD) is a Strong Momentum Stock
Pediatrix Medical Group (MD) is a Top-Ranked Growth Stock: Should You Buy?